Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2025.1730518 Correction Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma XiongShuanglong 1 † Writing – original draft YangChengxiang 1 † Data curation Writing – review & editing FuKaiwen 1 Investigation Writing – review & editing LiaoXingyun 1 Methodology Writing – review & editing DingYao 1 Investigation Writing – review & editing ZhouKexue 1 Conceptualization Writing – review & editing ZhangLi 1 Writing – review & editing TengYan 1 Investigation Writing – review & editing WuChunman 2 Methodology Writing – review & editing LiYongsheng 1 * Writing – review & editing LiangHoujie 3 * Funding acquisition Supervision Writing – review & editing LiYan 1 * Writing – review & editing Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China Nanjing Geneseeq Technology Inc, Nanjing, China Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China Correspondence: Yongsheng Li, yongshengli2005@163.com; Yan Li, pipili@sina.com; Houjie Liang, lianghoujie_1259@sina.com

These authors have contributed equally to this work

 18 11 2025 2025 15 1730518 22 10 2025 06 11 2025 28 10 2025 Copyright © 2025 Xiong, Yang, Fu, Liao, Ding, Zhou, Zhang, Teng, Wu, Li, Liang and Li. 2025 Xiong, Yang, Fu, Liao, Ding, Zhou, Zhang, Teng, Wu, Li, Liang and Li https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma By Xiong S, Yang C, Fu K, Liao X, Ding Y, Zhou K, Zhang L, Teng Y, Wu C, Li Y, Liang H and Li Y (2025) Front. Oncol. 15:1527719. doi: 10.3389/fonc.2025.1527719 lung large-cell neuroendocrine carcinoma Surufatinib toripalimab immune microenvironment TMB section-at-acceptance Cancer Immunity and Immunotherapy

Author “Chunman Wu” was erroneously assigned to affiliation “Chongqing University Cancer Hospital”. This affiliation has now been removed for author “Chunman Wu”.

Affiliation “Nanjing Geneseeq Technology Inc, Nanjing, China” was omitted for author “Chunman Wu”. This affiliation has now been added for author “Chunman Wu”. Shuanglong Xiong1†, Chengxiang Yang1†, Kaiwen Fu1, Xingyun Liao1, Yao Ding1, Kexue Zhou1, Li Zhang1, Yan Teng1, Chunman Wu2, Yongsheng Li1*, Houjie Liang3* and Yan Li1*

1Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China, 2Nanjing Geneseeq Technology Inc, Nanjing, China, 3Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.

The Conflict of interest statement has been correct to “Author CW was employed by Nanjing Geneseeq Technology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.”

The funder “1. Beijing Xisike Clinical Oncology Research Foundation (Y-HH202102-0200); 2. Senior Medical Talents Program of Chongqing for Young and Middle-aged (2020GDRC005)” were erroneously omitted.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland